CUV 1.60% $14.74 clinuvel pharmaceuticals limited

Time for a Change

  1. 5 Posts.
    lightbulb Created with Sketch. 3
    SP ~ $34 (2019) - ~$15 (2024)

    - The longterm CEO is the 2nd largest shareholder with, imo, an inappropriate compensation package for a public company of its size?

    - The Board comprises directors with, imo, questionable independence & experience and one cannot imagine they are providing sufficient independent challenge to the executive management team?

    - The CEO should take this lifestyle Company private rather than continue to fool himself and others that it is being run as an independent public company in the interest of ALL shareholders. PE would not tolerate the cost base, profligacy and performance

    - Time for a change?
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.